mTOR Inhibitor Timing for T Cell Memory
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccines often require multiple doses to induce adequate immunological memory, which can be costly and reduce compliance, highlighting a need for methods to enhance antigen-specific T cell immune responses for rapid vaccination and improved efficacy.
Innovation Solution
Administering a therapeutically effective amount of an mTOR inhibitor, such as rapamycin, during the contraction phase of a T cell response or at any time prior to or subsequent to antigen challenge, in combination with an antigen, to enhance antigen-specific T cell immune responses by increasing the number or quality of antigen-specific T cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If multiple doses of vaccine are administered to induce adequate immunological memory, then the quality of immune response is improved, but the cost increases and compliance decreases
Solution Approach 1:
The patent applies preliminary action by administering the mTOR inhibitor before antigen challenge or during the contraction phase to pre-condition the immune system. This timing allows the inhibitor to optimize T cell differentiation and memory formation in advance, enabling a single vaccine dose to achieve the same immunological memory that would otherwise require multiple doses
Solution Approach 2:
The patent changes the temporal parameter of mTOR inhibition by administering it at specific time windows (before antigen challenge or during contraction phase) rather than continuously. This parameter change optimizes the balance between T cell proliferation and memory differentiation, achieving enhanced immunological memory with reduced vaccination frequency
2Reliability
If multiple doses of vaccine are administered to induce adequate immunological memory, then the quality of immune response is improved, but the cost increases
Solution Approach 1:
By administering the mTOR inhibitor in advance or during the contraction phase, the patent enables a single vaccine dose to generate sufficient immunological memory, thereby eliminating the need for multiple expensive booster shots and reducing overall vaccination costs
Solution Approach 2:
The mTOR inhibitor enables the immune system to self-optimize memory formation by modulating the contraction phase dynamics. The immune system naturally progresses through expansion and contraction phases, and the inhibitor enhances this self-organizing process to produce durable memory with minimal external intervention
3Reliability
If mTOR inhibitors are administered to enhance T cell responses, then the quality of memory T cells is improved, but the risk of immunosuppression increases
Solution Approach 1:
The patent applies periodic action by administering the mTOR inhibitor in specific time windows (before antigen challenge or during contraction phase) rather than continuously. This intermittent timing allows T cell expansion to proceed normally while optimizing memory differentiation during the contraction phase, thereby enhancing memory quality without causing prolonged immunosuppression
Solution Approach 2:
The patent applies local quality by targeting the contraction phase specifically for mTOR inhibition. Different phases of the immune response have different functional requirements: expansion requires mTOR activity for proliferation, while memory formation benefits from mTOR inhibition. By applying the inhibitor locally to the contraction phase, the patent optimizes memory quality while preserving necessary immune functions
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method significantly enhances antigen-specific T cell immune responses, increasing the proportion of high-quality memory T cells and improving the expression of CD127, CD62L, Bcl-2, and CD27 while decreasing KLRG-1 expression in CD8+ T cells, leading to enhanced immunological memory and vaccine efficacy.
Implementation Method 1
Rapamycin is a natural product produced by the bacterium Streptomyces hygroscopicus that can inhibit mTOR through association with its intracellular receptor FK-506 binding protein 12 (FKBP12). The FKBP12-rapamycin complex binds directly to the FKBP12-rapamycin binding domain of mTOR.
Data Source
AI summary
It is disclosed herein that treatment of a subject with an mTOR inhibitor enhances antigen-specific T cell immune responses. Thus, provided herein is a method of enhancing an antigen-specific T cell response in a subject by administering to the subject a therapeutically effective amount of an mTOR inhibitor. The antigen can be any antigen, such as an antigen from a pathogen or a vaccine, or a tumor antigen. In some embodiments, the method further comprises administering to the subject a vaccine, such as a virus vaccine or a cancer vaccine. The mTOR inhibitor can be administered either before or after vaccination to enhance the quantity and quality of the T cell immune response and immunological memory. In some examples, the mTOR inhibitor is rapamycin or a rapamycin analog.